UNSPSC 51161731: Ambroxol/salbutamol

This classification denotes a combination drug composed of two constituents: a mucolytic and bronchodilator and beta-adrenergic agonist, as more fully appears.

The first constituent, ambroxol (51162702), is an expectorant and amino-alcohol that bears the molecular formula C13H18BR2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 200168S0CL, chemically known as 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol but more generally known as ambroxol [EU/ESIS 242-500-3]; ambroxol comes in forms acefyllinate [0HM1E174TN], base, and hydrochloride [CC995ZMV90].

UNSPSC 51161731 Ambroxol/salbutamol is a Commodity code, but the recent state and local contract opportunities posted under it do not align with the code's nominal scope. The four recent solicitations involve naloxone and drug deactivation systems, on-site pharmacy services for county employee health plans, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing—none of which are ambroxol or salbutamol respiratory formulations. The mismatch suggests either tagging error on the part of the issuing bodies or that the code is being used as a catch-all for pharmaceutical procurement activity broadly rather than the specific bronchodilator-mucolytic combination the code name indicates.

The issuing bodies include a county health department (Seminole County, Florida), a county government employee health plan administrator (Hall County, Georgia), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota MMCAP, with Oregon participation). Recent opportunities span Florida, Georgia, Texas, and Minnesota. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. Hall County issued an RFQ/P #47-010 (due June 4, 2026) for on-site pharmacy services at its family health center clinic covering approximately 3,005 covered individuals across multiple health plan types. Texas HHS Commission released an RFI (HHS0017013, April 3, 2026 response deadline) to gather vendor capabilities for a direct-to-manufacturer prescription program. MMCAP's RFP (S1070000015802, due March 26, 2026) establishes contracts for generic pharmaceuticals and OTC products through three authorized wholesalers. The code shows little relevant recent activity for the specific pharmaceutical product its name denotes.